Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) research hub
5 indexed studies · 3 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
This clinical trial looks at whether combining two medicines, eplontersen and ALXN2220, is safe and effective for adults with a heart condition called ATTR-CM. Researchers want to find out if using both treatments together helps improve breathing, exercise fitness, and overall heart health better than taking eplontersen with a dummy drug.
Germany · Italy · Spain - recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study is testing a new injection called ION-682884 for adults with a serious heart condition called ATTR-CM. Researchers want to find out if this medicine can protect the heart, lower the need for hospital care, and help people live longer compared to a dummy treatment (placebo).
Czechia · Portugal · Sweden - active not recruiting
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
This study uses special heart scans (MRI) to see if a new medicine can help reduce a build-up of a substance called amyloid in the hearts of people with a condition called ATTR-CM. The scans will help doctors understand how the medicine affects the heart over time.
United States · Italy · Spain - active not recruitingPHASE3
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
This study is testing a new medicine, eplontersen, for a heart condition called ATTR amyloidosis. It aims to see if eplontersen works better than a dummy medicine (placebo) to improve the health of people with this condition.
United States · Argentina · Australia - enrolling by invitationPHASE3
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study looks at the long-term safety of a medicine called eplontersen for adults with a heart condition called ATTR-CM. It's for people who have already taken part in a related study to see how the treatment works over a longer time.
United States · Argentina · Australia